@article{485022a665b642309e0e997564d493b3,
title = "Cuprizone-treated mice, a possible model of schizophrenia, highlighting the simultaneous abnormalities of GABA, serine and glycine in hippocampus",
author = "Eisuke Hayakawa and Masahiro Ohgidani and Yoshinori Fujimura and Shigenobu Kanba and Daisuke Miura and Kato, {Takahiro A.}",
note = "Funding Information: This work was supported by a Grant-in-Aid for Scientific Research on (1) KAKENHI - the Japan Society for the Promotion of Science (to E.H.: 17K14968 ; to D. M.: 26713020 ; to T.A.K., M.O. and S.K.: 24650227 , 25293252 , 16H02666 , 26713039 , 26860933 , and 18H04042 ), (2) MEXT Funding-Project for Developing Innovation Systems Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program in Japan (D.M. and T. A. K.), (3) Innovative Areas “Glia Assembly” and “Will Dynamics” of The Ministry of Education, Culture, Sports, Science, and Technology, Japan ( 25117011 to S.K.; 16H06403 to T.A.K.), (4) The Japan Agency for Medical Research and Development (AMED) ( Yugo-Nou JP18dm0107095 to T.A.K.: Seishin-Syogai Taisaku-Jigyo JP18dk0307075 to S.K. and T.A.K.), (5) Young Principal Investigators' Research Grant of Innovation Center for Medical Redox Navigation, Kyushu University (to T.A.K.), (6) Takeda Medical Research Foundation (to T.A.K.), and (7) the SENSHIN Medical Research Foundation (to T.A.K., M.O., and S.K.). The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. Funding Information: This work was supported by a Grant-in-Aid for Scientific Research on (1) KAKENHI - the Japan Society for the Promotion of Science (to E.H.: 17K14968; to D. M.: 26713020; to T.A.K., M.O. and S.K.: 24650227, 25293252, 16H02666, 26713039, 26860933, and 18H04042), (2) MEXT Funding-Project for Developing Innovation Systems Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program in Japan (D.M. and T. A. K.), (3) Innovative Areas ?Glia Assembly? and ?Will Dynamics? of The Ministry of Education, Culture, Sports, Science, and Technology, Japan (25117011 to S.K.; 16H06403 to T.A.K.), (4) The Japan Agency for Medical Research and Development (AMED) (Yugo-Nou JP18dm0107095 to T.A.K.: Seishin-Syogai Taisaku-Jigyo JP18dk0307075 to S.K. and T.A.K.), (5) Young Principal Investigators' Research Grant of Innovation Center for Medical Redox Navigation, Kyushu University (to T.A.K.), (6) Takeda Medical Research Foundation (to T.A.K.), and (7) the SENSHIN Medical Research Foundation (to T.A.K., M.O., and S.K.). The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. We acknowledge the excellent technical assistance provided by Ms. Ayaka Maeda, Ms. Yuka Matsushita, Mr. Shogo Inamine and Ms. Aya Yamada.",
year = "2019",
month = aug,
doi = "10.1016/j.schres.2019.06.010",
language = "English",
volume = "210",
pages = "326--328",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
}
